SMAM
IOVA icon

Sugar Maple Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Sugar Maple Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.62M Buy
176,492
+41,492
+31% +$297K 1.49% 20
2026
Q2 		$562K Buy
135,000
+15,000
+13% +$57K 0.36% 48
2026
Q1 		$421K Buy
120,000
+10,000
+9% +$32K 0.26% 57
2025
Q4 		$300K Buy
+110,000
New +$254K 0.2% 67

Other funds holding IOVA

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $415M AUM 17.23% 1-Year Est. Return
HCG
Haven Capital Group Westlake Village, California $131M AUM 23.95% 1-Year Est. Return
AWM
Able Wealth Management Toms River, New Jersey $455M AUM 13.63% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Sugar Maple Asset Management's IOVA Position: Q3 2026 in Review

Sugar Maple Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 31% in Q3 2026, buying an estimated $297K and bringing the position to 176,492 shares worth $2.62M. The position accounts for 1.49% of the portfolio, ranked #20.

Sugar Maple Asset Management first reported a position in IOVA in Q4 2025 and has held it in 4 quarters since. 13 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Sugar Maple Asset Management held 176,492 shares of Iovance Biotherapeutics worth $2.62M as of Q3 2026.
  • Sugar Maple Asset Management bought 41,492 Iovance Biotherapeutics shares in Q3 2026, an estimated $297K.
  • Iovance Biotherapeutics made up 1.49% of Sugar Maple Asset Management's portfolio in Q3 2026, its #20 holding.
  • Sugar Maple Asset Management first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 4 quarters since.
  • 13 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Sugar Maple Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.